;PMID: 7627815
;source_file_2907.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..159] = [t:45..159]
;2)section:[e:163..222] = [t:163..222]
;3)section:[e:226..323] = [t:226..323]
;4)sentence:[e:327..511] = [t:327..511]
;5)sentence:[e:512..749] = [t:512..749]
;6)sentence:[e:750..834] = [t:750..834]
;7)sentence:[e:835..995] = [t:835..995]
;8)sentence:[e:996..1160] = [t:996..1160]
;9)sentence:[e:1161..1264] = [t:1161..1264]
;10)sentence:[e:1266..1405] = [t:1266..1405]
;11)section:[e:1409..1453] = [t:1409..1453]

;section 0 Span:0..39
;Cancer Gene Ther.  1994 Dec;1(4):253-8.
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..11] Gene) (NNP:[12..16] Ther)
        (.:[16..17] .) (CD:[19..23] 1994) (CC:[24..29] Dec;1)
        (-LRB-:[29..30] -LRB-) (CD:[30..31] 4) (-RRB-:[31..32] -RRB-)
        (CD:[32..36] :253) (::[36..37] -) (CD:[37..39] 8.)))

;sentence 1 Span:45..159
;Immunomodulatory effects of human neuroblastoma cells transduced with a 
;retroviral vector encoding interleukin-2.
;[79..98]:malignancy-type:"neuroblastoma cells"
;[145..158]:gene-generic:"interleukin-2"
(SENT
  (NP-HLN
    (NP (JJ:[45..61] Immunomodulatory) (NNS:[62..69] effects))
    (PP (IN:[70..72] of)
      (NP
        (NP (JJ:[73..78] human)
           (NN:[79..92] neuroblastoma) (NNS:[93..98] cells))
        (VP (VBN:[99..109] transduced)
          (NP (-NONE-:[109..109] *))
          (PP (IN:[110..114] with)
            (NP
              (NP (DT:[115..116] a) (JJ:[118..128] retroviral)
                  (NN:[129..135] vector))
              (VP (VBG:[136..144] encoding)
                (NP (NN:[145..158] interleukin-2))))))))
    (.:[158..159] .)))

;section 2 Span:163..222
;Leimig T, Foreman N, Rill D, Coze C, Holladay M, Brenner M.
(SEC
  (FRAG (NNP:[163..169] Leimig) (NNP:[170..171] T) (,:[171..172] ,)
        (NNP:[173..180] Foreman) (NNP:[181..182] N) (,:[182..183] ,)
        (NNP:[184..188] Rill) (NNP:[189..190] D) (,:[190..191] ,)
        (NNP:[192..196] Coze) (NNP:[197..198] C) (,:[198..199] ,)
        (NNP:[200..208] Holladay) (NNP:[209..211] M,) (NNP:[212..219] Brenner)
        (NNP:[220..222] M.)))

;section 3 Span:226..323
;Department of Hematology/Oncology, St Jude Children's Research Hospital, 
;Memphis, TN 38105, USA.
(SEC
  (FRAG (NNP:[226..236] Department) (IN:[237..239] of)
        (NNP:[240..250] Hematology) (NNP:[250..259] /Oncology) (,:[259..260] ,)
        (NNP:[261..263] St) (NNP:[264..268] Jude) (NNP:[269..277] Children)
        (POS:[277..279] 's) (NNP:[280..288] Research) (NNP:[289..297] Hospital)
        (,:[297..298] ,) (NNP:[300..307] Memphis) (,:[307..308] ,)
        (NN:[309..311] TN) (CD:[312..317] 38105) (,:[317..318] ,)
        (NNP:[319..322] USA) (.:[322..323] .)))

;sentence 4 Span:327..511
;We have investigated whether retroviral mediated transfer of the IL-2 gene 
;renders human neuroblastoma cells immunogenic, justifying their use in a 
;clinical tumor immunization study.
;[392..396]:gene-rna:"IL-2"
;[417..436]:malignancy-type:"neuroblastoma cells"
(SENT
  (S
    (NP-SBJ (PRP:[327..329] We))
    (VP (VBP:[330..334] have)
      (VP (VBN:[335..347] investigated)
        (SBAR (IN:[348..355] whether)
          (S
            (NP-SBJ
              (NP (JJ:[356..366] retroviral) (VBN:[367..375] mediated)
                  (NN:[376..384] transfer))
              (PP (IN:[385..387] of)
                (NP (DT:[388..391] the) (NN:[392..396] IL-2)
                    (NN:[397..401] gene))))
            (VP (VBZ:[403..410] renders)
              (S
                (NP-SBJ (JJ:[411..416] human)
                   (NN:[417..430] neuroblastoma) (NNS:[431..436] cells))
                (ADJP-PRD (JJ:[437..448] immunogenic)))
              (,:[448..449] ,)
              (S-ADV
                (NP-SBJ (-NONE-:[449..449] *))
                (VP (VBG:[450..460] justifying)
                  (NP
                    (NP (PRP$:[461..466] their) (NN:[467..470] use))
                    (PP (IN:[471..473] in)
                      (NP (DT:[474..475] a) (JJ:[477..485] clinical)
                        (NML (NN:[486..491] tumor) (NN:[492..504] immunization))
                        (NN:[505..510] study)))))))))))
    (.:[510..511] .)))

;sentence 5 Span:512..749
;Fourteen neuroblastoma cell lines were  established from patients with
;disseminated neuroblastoma and transduced with  the vector G1Ncvl2, which
;contains the neomycin phosphotransferase gene and the  cDNA of the human
;interleukin-2 gene.
;[521..534]:malignancy-type:"neuroblastoma"
;[596..609]:malignancy-type:"neuroblastoma"
;[670..697]:gene-rna:"neomycin phosphotransferase"
;[730..743]:gene-rna:"interleukin-2"
(SENT
  (S
    (NP-SBJ-1 (CD:[512..520] Fourteen) (NN:[521..534] neuroblastoma)
              (NN:[535..539] cell) (NNS:[540..545] lines))
    (VP (VBD:[546..550] were)
      (VP
        (VP (VBN:[552..563] established)
          (NP-1 (-NONE-:[563..563] *))
          (PP (IN:[564..568] from)
            (NP
              (NP (NNS:[569..577] patients))
              (PP (IN:[578..582] with)
                (NP (VBN:[583..595] disseminated) (NN:[596..609] neuroblastoma))))))
        (CC:[610..613] and)
        (VP (VBN:[614..624] transduced)
          (NP-1 (-NONE-:[624..624] *))
          (PP-CLR (IN:[625..629] with)
            (NP
              (NP (DT:[631..634] the) (NN:[635..641] vector))
              (NP
                (NP (NN:[642..649] G1Ncvl2))
                (,:[649..650] ,)
                (SBAR
                  (WHNP-2 (WDT:[651..656] which))
                  (S
                    (NP-SBJ-2 (-NONE-:[656..656] *T*))
                    (VP (VBZ:[657..665] contains)
                      (NP
                        (NP (DT:[666..669] the)
                           (NN:[670..678] neomycin)
                           (NN:[679..697] phosphotransferase)
                          (NN:[698..702] gene))
                        (CC:[703..706] and)
                        (NP
                          (NP (DT:[707..710] the) (NN:[712..716] cDNA))
                          (PP (IN:[717..719] of)
                            (NP (DT:[720..723] the) (JJ:[724..729] human)
                                (NN:[730..743] interleukin-2)
                                (NN:[744..748] gene))))))))))))))
    (.:[748..749] .)))

;sentence 6 Span:750..834
;Clones secreting > 150 pg/10(6) cells/24 h  of IL-2 were selected for further
;study.
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[750..756] Clones))
      (VP (VBG:[757..766] secreting)
        (NP
          (NP
            (QP (SYM:[767..768] >) (CD:[769..772] 150))
            (NN:[773..775] pg))
          (PP (SYM:[775..776] /)
            (NP (CD:[776..781] 10-LRB-6-RRB-) (NNS:[782..787] cells)))
          (PP (SYM:[787..788] /)
            (NP
              (NP (CD:[788..790] 24) (NN:[791..792] h))
              (PP (IN:[794..796] of)
                (NP (NN:[797..801] IL-2))))))))
    (VP (VBD:[802..806] were)
      (VP (VBN:[807..815] selected)
        (NP-1 (-NONE-:[815..815] *))
        (PP (IN:[816..819] for)
          (NP (JJ:[820..827] further) (NN:[828..833] study)))))
    (.:[833..834] .)))

;sentence 7 Span:835..995
;Secretion of IL-2 was maintained for at  least 3 weeks in nonselective media,
;implying that production of the cytokine  would continue under in vivo
;conditions.
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[835..844] Secretion))
      (PP (IN:[845..847] of)
        (NP (NN:[848..852] IL-2))))
    (VP (VBD:[853..856] was)
      (VP (VBN:[857..867] maintained)
        (NP-1 (-NONE-:[867..867] *))
        (PP (IN:[868..871] for)
          (NP
            (NP
              (QP (IN:[872..874] at) (JJS:[876..881] least) (CD:[882..883] 3))
              (NNS:[884..889] weeks))
            (PP (IN:[890..892] in)
              (NP (JJ:[893..905] nonselective) (NNS:[906..911] media)))))
        (,:[911..912] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[912..912] *))
          (VP (VBG:[913..921] implying)
            (SBAR (IN:[922..926] that)
              (S
                (NP-SBJ
                  (NP (NN:[927..937] production))
                  (PP (IN:[938..940] of)
                    (NP (DT:[941..944] the) (NN:[945..953] cytokine))))
                (VP (MD:[955..960] would)
                  (VP (VB:[961..969] continue)
                    (PP (IN:[970..975] under)
                      (NP
                        (ADJP (FW:[976..978] in) (FW:[979..983] vivo))
                        (NNS:[984..994] conditions)))))))))))
    (.:[994..995] .)))

;sentence 8 Span:996..1160
;Co-culture of IL-2 transduced cell  lines with patient lymphocytes induced
;potent cytotoxic activity against both  transduced and parental neuroblastoma
;cell lines.
;[1135..1148]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ
      (NP (AFX:[996..998] Co) (HYPH:[998..999] -) (NN:[999..1006] culture))
      (PP (IN:[1007..1009] of)
        (NP
          (NP
            (ADJP (NN:[1010..1014] IL-2) (VBN:[1015..1025] transduced))
            (NN:[1026..1030] cell) (NNS:[1032..1037] lines))
          (PP (IN:[1038..1042] with)
            (NP (NN:[1043..1050] patient) (NNS:[1051..1062] lymphocytes))))))
    (VP (VBD:[1063..1070] induced)
      (NP
        (NP (JJ:[1071..1077] potent) (JJ:[1078..1087] cytotoxic)
            (NN:[1088..1096] activity))
        (PP (IN:[1097..1104] against)
          (NP (CC:[1105..1109] both)
            (NP (VBN:[1111..1121] transduced)
              (NML-1 (-NONE-:[1121..1121] *P*)))
            (CC:[1122..1125] and)
            (NP (JJ:[1126..1134] parental) (NN:[1135..1148] neuroblastoma)
              (NML-1 (NN:[1149..1153] cell) (NNS:[1154..1159] lines)))))))
    (.:[1159..1160] .)))

;sentence 9 Span:1161..1264
;This activity was HLA  unrestricted, and predominantly mediated by CD16+ or
;CD56+ and CD8- lymphocytes.
;[1179..1182]:gene-generic:"HLA"
;[1228..1232]:gene-protein:"CD16"
;[1237..1241]:gene-protein:"CD56"
;[1247..1250]:gene-protein:"CD8"
(SENT
  (S
    (NP-SBJ-1 (DT:[1161..1165] This) (NN:[1166..1174] activity))
    (VP
      (VP (VBD:[1175..1178] was)
        (ADJP-PRD (NN:[1179..1182] HLA) (JJ:[1184..1196] unrestricted)))
      (,:[1196..1197] ,) (CC:[1198..1201] and)
      (VP
        (ADVP (RB:[1202..1215] predominantly))
        (VBN:[1216..1224] mediated)
        (NP-1 (-NONE-:[1224..1224] *))
        (PP (IN:[1225..1227] by)
          (NP-LGS
            (NP
              (NP
                (NML (NN:[1228..1232] CD16) (SYM:[1232..1233] +))
                (NML-2 (-NONE-:[1233..1233] *P*)))
              (CC:[1234..1236] or)
              (NP
                (NML (NN:[1237..1241] CD56) (SYM:[1241..1242] +))
                (NML-2 (-NONE-:[1242..1242] *P*))))
            (CC:[1243..1246] and)
            (NP
              (NML (NN:[1247..1250] CD8) (SYM:[1250..1251] -))
              (NML-2 (NNS:[1252..1263] lymphocytes)))))))
    (.:[1263..1264] .)))

;sentence 10 Span:1266..1405
;These data form the preclinical justification for our current immunization 
;protocol for patients with relapsed or resistant neuroblastoma.
;[1391..1404]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ (DT:[1266..1271] These) (NNS:[1272..1276] data))
    (VP (VBP:[1277..1281] form)
      (NP
        (NP (DT:[1282..1285] the) (JJ:[1286..1297] preclinical)
            (NN:[1298..1311] justification))
        (PP (IN:[1312..1315] for)
          (NP
            (NP (PRP$:[1316..1319] our) (JJ:[1320..1327] current)
                (NN:[1328..1340] immunization) (NN:[1342..1350] protocol))
            (PP (IN:[1351..1354] for)
              (NP
                (NP (NNS:[1355..1363] patients))
                (PP (IN:[1364..1368] with)
                  (NP
                    (NP (VBN:[1369..1377] relapsed)
                      (NML-1 (-NONE-:[1377..1377] *P*)))
                    (CC:[1378..1380] or)
                    (NP (JJ:[1381..1390] resistant)
                      (NML-1 (NN:[1391..1404] neuroblastoma)))))))))))
    (.:[1404..1405] .)))

;section 11 Span:1409..1453
;PMID: 7627815 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1409..1413] PMID) (::[1413..1414] :) (CD:[1415..1422] 7627815)
        (NN:[1423..1424] -LSB-) (NNP:[1424..1430] PubMed) (::[1431..1432] -)
        (NN:[1433..1440] indexed) (IN:[1441..1444] for)
        (NNP:[1445..1453] MEDLINE-RSB-)))
